{
  "docId": "019de076-7d6c-774e-85e8-ffe50da37251",
  "docSlug": "0b0d701714d17efa78c23c196990e90c",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 37,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a cross-trial comparison to highlight the efficacy of Olvi-Vec in heavily pre-treated patients.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7d6c-774e-85e8-ffe50da37251/15",
  "deckHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251",
  "deckJsonHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251.json",
  "deckAnchorHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.63,
        "x": 0.348,
        "y": 0.148
      },
      "kind": "callout",
      "text": "While clinical remissions are obtainable, a majority of patients will relapse. Genelux looks to take an all-comers approach",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "322c4e8e-1ee7-4371-8496-b9c70cea2275",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.365,
        "y": 0.248
      },
      "kind": "chart",
      "text": "Bar chart comparing RECIST1.1, CA-125, and PFS-6-month outcomes across various clinical studies.",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dcc553d-03a7-4945-aecb-6c4597d9857f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.31,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "list",
      "text": "Key Clinical Takeaways: Olvi-Vec addresses a broad and underserved pool of patients. Olvi-Vec trial inclusion criteria allows patients regardless of tumor biomarkers, platinum refractory tumors, or number of prior lines of treatment. Olvi-Vec Phase 2 results approach results in less pre-treated platinum-sensitive patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58feaa53-d5d1-4a27-bf96-4ab27ceff4fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.365,
        "y": 0.8
      },
      "kind": "source-note",
      "text": "References and disclaimer regarding cross-trial comparison limitations.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eef4a327-9d71-4b80-9e1a-7de135e91879",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.32,
        "w": 0.6,
        "x": 0.365,
        "y": 0.47
      },
      "kind": "table",
      "text": "Table listing study names, prior lines of treatment, and regimens for platinum-resistant/refractory and platinum-sensitive patients.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "283b32d5-64fa-4482-9193-e55bc255b8f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "“Allcomers” Approach May Reset Life Clock of Heavily Pre-treated Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0048e0e5-d5fa-4adc-84b5-9b2dfa7a428d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "50d6b40c-d250-4d90-8265-2756bb5cce0a",
      "evidence": "table/data: Table listing study names, prior lines of treatment, and regimens for platinum-resistant/refractory and platinum-sensitive patients.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "26abf432-c051-4959-ad9f-b7e65e77ea03",
      "evidence": "Comparison of Olvi-Vec against multiple other clinical studies in a table and bar chart format.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 15,
      "from": 15,
      "beatId": "5d6ec1a0-78ec-4c0e-a90d-8d7deda0b64a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The market size is implied to be large, with a broad and underserved pool of patients.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}